Cover Image
市場調查報告書

女性醫療的全球市場預測 2017-2027年:停經後骨質疏鬆症·荷爾蒙避孕藥·停經·不孕·子宮內膜異位症·多發性卵巢症候群

Global Women's Healthcare Market Forecast 2017-2027: Postmenopausal Osteoporosis, Hormonal Contraceptives, Menopause, Infertility, Endometriosis, Polycystic Ovary Syndrome

出版商 Visiongain Ltd 商品編碼 553348
出版日期 內容資訊 英文 154 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
女性醫療的全球市場預測 2017-2027年:停經後骨質疏鬆症·荷爾蒙避孕藥·停經·不孕·子宮內膜異位症·多發性卵巢症候群 Global Women's Healthcare Market Forecast 2017-2027: Postmenopausal Osteoporosis, Hormonal Contraceptives, Menopause, Infertility, Endometriosis, Polycystic Ovary Syndrome
出版日期: 2017年07月14日 內容資訊: 英文 154 Pages
簡介

全球女性醫療市場上收益在2016年推算為311億美元,預計在預測期間前期將以3.8%的年複合成長率 (CAGR) 成長。在全球女性醫療市場上的各種市場區隔中,停經後骨質疏鬆症市場區隔佔最大優勢,2016年佔36.99%的佔有率。

本報告涵括全球女性醫療市場,提供市場概要,市場上主要的子市場之收益預測·SWOT分析,主要地區·國家市場的收益預測,開發中產品相關討論,市場成長的影響因素,及主要企業等系統性資訊。

第1章 調查概要

第2章 女性醫療問題的簡介

  • 主要的女性醫療課題是什麼?
  • 女性醫療問題的原因和風險因素是什麼?
  • 女性醫療問題的診斷
  • 婦產科疾病的流行病學
  • 人的·經濟上的負擔
  • 女性醫療的問題:預防·治療

第3章 全球女性醫療市場簡介

  • 全球女性醫療市場:各應用領域
    • 停經後骨質疏鬆症
    • 荷爾蒙避孕藥
    • 停經
    • 不孕
    • 子宮內膜異位症
    • 多發性卵巢症候群

第4章 全球女性醫療市場規模·預測

  • 市場區隔:各應用領域
    • 全球市場:停經後骨質疏鬆症
    • 全球市場:荷爾蒙避孕藥
    • 全球市場:停經
    • 全球市場:不孕
    • 全球市場:子宮內膜異位症
    • 全球市場:多發性卵巢症候群
  • 女性醫療的主要產品

第5章 主要國家市場預測

  • 全球女性醫療治療藥市場明細
  • 美國·南美女性醫療治療藥市場
  • EU5個國家女性醫療治療藥市場
  • 其他的歐洲女性醫療治療藥市場
  • 日本的女性醫療治療藥市場
  • 其他 (ROW) 的女性醫療治療藥市場

第6章 全球女性醫療市場促進成長要素

  • 高齡女性人口的增加
  • 對有潛力開發平台分子上市的期待
  • 停經後骨質疏鬆症的盛行率增加
  • 技術性進步的產品介紹

第7章 全球女性醫療市場課題

  • 主要暢銷藥的專利到期
  • 有效治療的不足
  • 替代治療選項的替代威脅
  • MRT治療的高成本

第8章 全球女性醫療市場趨勢

  • 策略性聯盟的增加
  • 啟發計劃·舉措
  • 非荷爾蒙療法的病例轉移

第9章 開發平台分子

第10章 全球女性醫療市場上主要企業

  • Bayer
  • Eli Lily and Company
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Novartis
  • Sanofi
  • Amgen
  • Novo Nordisk
  • AbbVie
  • Bristol-Myers Squibb
  • 其他有潛力的供應商

第11章 結論

圖表

目錄
Product Code: PHA0212

The revenue of the women's healthcare market in 2016 is estimated at $31.1bn and is expected to grow at a CAGR of 3.8% in the first half of the forecast period. Among various segments in the Women's Healthcare market, the Postmenopausal Osteoporosis segment dominated the Global Women's Healthcare market with a share of 36.99% in 2016.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 154-page report you will receive 96 charts - all unavailable elsewhere.

The 154-page report provides clear detailed insight into the women's healthcare market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Global Women's Healthcare market forecasts from 2017-2027
  • This report also breaks down the revenue forecast and SWOT Analysis for the main submarkets:
    • Postmenopausal Osteoporosis
    • Hormonal Contraceptives
    • Infertility
    • Endometriosis
    • Polycystic Ovary Syndrome
  • This report provides individual revenue forecasts to 2027 for these regional and national markets:
    • The US and Latin America
    • Japan
    • The UK
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
    • Rest of the World
  • This report provides discussion on pipeline products in various stages of clinical trials and regulatory approval
  • This report also discusses the drivers, challenges and trends that affect the global women's healthcare market
  • Our study discusses the selected leading companies that are the major players in the global women's healthcare market
    • Bayer
    • Eli Lilly
    • Merck & Co.
    • Pfizer
    • Sanofi
    • Amgen
    • Novo Nordisk
    • AbbVie
    • Bristol-Myers Squibb (BMS)

Visiongain's study is intended for anyone requiring commercial analyses for the women's healthcare market. You find data, trends and predictions.

Buy our report today Global Women's Healthcare Market Forecast 2017-2027: Postmenopausal Osteoporosis, Hormonal Contraceptives, Menopause, Infertility, Endometriosis, Polycystic Ovary Syndrome.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Overview of the Global Women's Healthcare Market
  • 1.2. Why You Should Read This Report
  • 1.3. How This Report Delivers
  • 1.4. Key Questions Answered by This Analytical Report Include:
  • 1.5. Who is This Report For?
  • 1.6. Methodology
    • 1.6.1. Primary Research
    • 1.6.2. Secondary Research
    • 1.6.3. Market Evaluation & Forecasting Methodology
  • 1.7. Frequently Asked Questions (FAQ)
  • 1.8. Associated Visiongain Reports
  • 1.9. About Visiongain

2. Introduction to the Woman's Health Issue

  • 2.1. What are the major women's health issues?
  • 2.2. What are the causes and risk factors of women's health issues?
    • 2.2.1. Modern Urbanization
      • 2.2.1.1. Alcohol Intake:
      • 2.2.1.2. Smoking:
      • 2.2.1.3. Unhealthy diet
    • 2.2.2. Social Restriction and Emotional Factors
    • 2.2.3. Pregnancy
    • 2.2.4. Malnutrition
    • 2.2.5. Obesity
    • 2.2.6. Age
  • 2.3. Diagnosis of Women's Health Issues
    • 2.3.1. Diagnosis of Breast Cancer
    • 2.3.2. Diagnosis of Osteoporosis
    • 2.3.3. Diagnosis of Endometriosis
    • 2.3.4. Diagnosis of polycystic ovary syndrome
      • 2.3.4.1. Ultrasound
      • 2.3.4.2. Hormonal blood tests
      • 2.3.4.3. Other blood tests
  • 2.4. Epidemiology of Women's diseases
    • 2.4.1. Epidemiology of Postmenopausal Osteoporosis:
      • 2.4.1.1. Projections:
    • 2.4.2. Epidemiology of Infertility in Women:
    • 2.4.3. Epidemiology of Endometriosis:
    • 2.4.4. Epidemiology of polycystic ovary syndrome
  • 2.5. Humanistic and Economic Burden
    • 2.5.1. Mortality
    • 2.5.2. Morbidity
      • 2.5.2.1. Years of Life Lost(YLL)
        • 2.5.2.1.1. Cardiovascular Disease
        • 2.5.2.1.2. Dyslipidaemia
        • 2.5.2.1.3. Hypertension
        • 2.5.2.1.4. Obesity
        • 2.5.2.1.5. Depression
    • 2.5.3. Economic Impact
  • 2.6. Women's Health Issues: Prevention and Treatment
    • 2.6.1. Lifestyle changes
    • 2.6.2. Pharmacotherapy
    • 2.6.3. Other treatments

3. Introduction to the Global Women Healthcare Market

  • 3.1. Global Women's Healthcare Market by Application
    • 3.1.1. Postmenopausal Osteoporosis
    • 3.1.2. Hormonal Contraceptives
    • 3.1.3. Menopause
    • 3.1.4. Infertility
    • 3.1.5. Endometriosis
    • 3.1.6. Polycystic Ovary Syndrome

4. Global Women's Healthcare Market Size and Forecast 2017-2027

  • 4.1. Market Segmentation by Application
    • 4.1.1. Global Postmenopausal Osteoporosis Market
      • 4.1.1.1. Market Overview
      • 4.1.1.2. Market Size and Forecast
      • 4.1.1.3. Competitive Analysis
      • 4.1.1.4. SWOT Analysis of the Global Postmenopausal Osteoporosis Drugs Market
    • 4.1.2. Global Hormonal Contraceptives Market
      • 4.1.2.1. Market Overview
      • 4.1.2.2. Market Size and Forecast
      • 4.1.2.3. Competitive Analysis
      • 4.1.2.4. SWOT Analysis of the Global Hormonal Contraceptives Market
    • 4.1.3. Global Menopause Market
      • 4.1.3.1. Market Overview
      • 4.1.3.2. Market Size and Forecast
      • 4.1.3.3. Competitive Analysis
      • 4.1.3.4. SWOT Analysis of the Global Menopause Market
    • 4.1.4. Global Infertility Market
      • 4.1.4.1. Market Overview
      • 4.1.4.2. Market Size and Forecast
      • 4.1.4.3. Competitive Analysis
      • 4.1.4.4. SWOT Analysis of Global Infertility Market
    • 4.1.5. Global Endometriosis Market
      • 4.1.5.1. Market Overview
      • 4.1.5.2. Market Size and Forecast
      • 4.1.5.3. Competitive Analysis
      • 4.1.5.4. SWOT Analysis of the Global Endometriosis Market
    • 4.1.6. Global Polycystic Ovary Syndrome Market
      • 4.1.6.1. Market Overview
      • 4.1.6.2. Market Size and Forecast
      • 4.1.6.3. Competitive Analysis
      • 4.1.6.4. SWOT Analysis of Global Polycystic Ovary Syndrome Market
  • 4.2. Leading Women Healthcare Products, 2016

5. Leading National Markets Forecast 2017-2027

  • 5.1. Geographical Breakdown of Global Women's Healthcare Drugs Market, 2016
  • 5.1. Women's Healthcare Drugs Market in the US and Latin America, 2016
    • 5.1.1. Market Forecast of the US and Latin America, 2017-2027
  • 5.2. Women's Healthcare Drugs Market in the EU5, 2016
    • 5.2.1. Market Forecast of the EU5 Countries, 2017-2027
      • 5.2.1.1. The UK
      • 5.2.1.2. Germany
      • 5.2.1.3. France
      • 5.2.1.4. Spain
      • 5.2.1.5. Italy
  • 5.3. Women's Healthcare Drugs Market in the Rest of Europe, 2016
  • 5.4. Women's Healthcare Drugs Market in the Japan, 2016
  • 5.5. Women's Healthcare Drugs Market in the Rest of the World, 2016

6. Global Women's Healthcare Market Growth Drivers

  • 6.1. Increase in Aging Female Population
  • 6.2. Expected Launch of Promising Pipeline Molecules
  • 6.3. Growing Prevalence of Postmenopausal Osteoporosis
  • 6.4. Introduction of Technologically Advanced Products

7. Global Women's Healthcare Market Challenges

  • 7.1. Patent Expiry of Major Blockbuster Drugs
  • 7.2. Lack of Effective Treatments
  • 7.3. Threat of Substitution by Alternative Treatment Options
  • 7.4. High Cost of MRT Therapies

8. Global Women's Healthcare Market Trends

  • 8.1. Rise in Strategic Partnerships
  • 8.2. Awareness Programs and Initiatives
  • 8.3. Paradigm Shift to Non-Hormonal Therapies

9. Pipeline Molecules

10. Leading Companies in the Global Women's Healthcare Market, 2016

  • 10.1. Bayer
    • 10.1.1. Bayer: Sales by Geography 2016
    • 10.1.2. Presence in the Women's Healthcare market
    • 10.1.3. SWOT Analysis
  • 10.2. Eli Lily and Company
    • 10.2.1. Eli Lily: Sales by Geography 2016
    • 10.2.2. Collaboration Agreement with Pfizer
    • 10.2.3. SWOT Analysis
  • 10.3. Merck & Co., Inc.
    • 10.3.1. Merck & Co.: Sales by Geography
    • 10.3.2. SWOT Analysis
  • 10.4. Pfizer Inc.
    • 10.4.1. Pfizer: Sales by Geography 2016
    • 10.4.2. Collaboration Agreement with Eli Lily and Company
    • 10.4.3. SWOT Analysis
  • 10.5. Novartis
    • 10.5.1. SWOT Analysis
  • 10.6. Sanofi
    • 10.6.1. SWOT Analysis
  • 10.7. Amgen
    • 10.7.1. SWOT Analysis
  • 10.8. Novo Nordisk
    • 10.8.1. SWOT Analysis
  • 10.9. AbbVie
    • 10.9.1. SWOT Analysis
  • 10.10. Bristol-Myers Squibb
    • 10.10.1. SWOT Analysis
  • 10.11. Other Prominent Vendors in Women's Healthcare Market

11. Conclusions

  • Appendices
  • Glossary
  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain report evaluation form

List of Tables

  • Table 2.1: Major women's health issue
  • Table 2.2: Women's Health Drugs (Company and Product)
  • Table 4.1: Global Women's Healthcare Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.2: Global Postmenopausal Osteoporosis Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.3: Global Hormonal Contraceptives Market Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.4: Global Menopause Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.5: Global Infertility Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.6: Global Endometriosis Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.7: Global Polycystic Ovary Syndrome Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.8: Revenues of the Leading Women Healthcare Products, 2016
  • Table 5.1: Global Women's Healthcare Drugs Market by Region: Revenue ($m), and Market Share (%), 2016
  • Table 5.2: Global Women's Healthcare Drugs Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 5.3: Global Women's Healthcare Drugs Market by Region: AGR (%), 2016-2027
  • Table 5.4: Global Women's Healthcare Drugs Market by Region: Market Share Forecast 2017-2027 (%)
  • Table 5.5: Women's Healthcare Drugs Market Forecast in the US 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.6: Women's Healthcare Drugs Market Forecast in the EU5 2016-2027: Revenue ($m), Global Market Share (%), EU5 Market Share (%)
  • Table 5.7: Women's Healthcare Drugs Market Forecast in EU5: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 5.8: Women's Healthcare Drugs Market Forecast in the UK: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 5.9: Women's Healthcare Drugs Market Forecast in Germany: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 5.10: Women's Healthcare Drugs Market Forecast in France: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 5.11: Women's Healthcare Drugs Market Forecast in Spain: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 5.12: Women's Healthcare Drugs Market Forecast in Italy: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 5.13: Women's Healthcare Drugs Market Forecast in RoE: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 5.14: Women's Healthcare Drugs Market Forecast in Japan: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 5.15: Women's Healthcare Drugs Market Forecast in Row: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 9.1: Active Pipeline Molecules under Development for Treating Epilepsy
  • Table 10.1: Bayer: Overview 2016
  • Table 10.2: Bayer: Pipeline
  • Table 10.3: Eli Lilly and Company: Overview 2016
  • Table 10.4: Merck: Overview 2016
  • Table 10.5: Pfizer: Overview 2016
  • Table 10.6: Pfizer: Pipeline
  • Table 10.7: Novartis: Overview 2016
  • Table 10.8: Novartis: Pipeline
  • Table 10.9: Sanofi: Overview 2016
  • Table 10.10: Amgen: Overview 2016
  • Table 10.11: Novo Nordisk: Overview 2016
  • Table 10.12: AbbVie: Overview 2016
  • Table 10.13: Bristol-Myers Squibb: Overview 2016
  • Table 10.14: Bristol-Myers Squibb: Overview 2016

List of Figures

  • Figure 1.1: Global Women's Health Market Segmentation by Application
  • Figure 2.1: Percentage of Women Affected by Endometriosis
  • Figure 2.2: DALY's due to Obesity in G7 and BRIC Nation: Absolute Number (million), 2015
  • Figure 3.1: Global Women's Health Market Segmentation by Application (%), 2016
  • Figure 4.1: Global Women's Healthcare Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)
  • Figure 4.2: Global Postmenopausal Osteoporosis Drugs Market Segmentation by Line of Therapy (%),2016
  • Figure 4.3: Global Postmenopausal Osteoporosis Drugs Market Segmentation by Line of Therapy (million), 2016
  • Figure 4.4: Global Women's Healthcare Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)
  • Figure 4.5: SWOT Analysis of the Global Postmenopausal Osteoporosis Drugs Market
  • Figure 4.6: Global Women's Healthcare Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)
  • Figure 4.7: SWOT Analysis of the Global Hormonal Contraceptives Market
  • Figure 4.8: Global Menopause Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)
  • Figure 4.9: SWOT Analysis of the Global Menopause Market
  • Figure 4.10: Global Infertility Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)
  • Figure 4.11: SWOT Analysis of the Global Infertility Market
  • Figure 4.12: Global Endometriosis Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)
  • Figure 4.13: SWOT Analysis of the Global Endometriosis Market
  • Figure 4.14: Global Polycystic Ovary Syndrome Market by Class of Drugs (%), 2016
  • Figure 4.15: Global Polycystic Ovary Syndrome Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)
  • Figure 4.16: SWOT Analysis of the Global Polycystic Ovary Syndrome Market
  • Figure 4.17: Market Share (%) of the Leading Women Healthcare Products, 2016
  • Figure 5.1: Global Women's Healthcare Drugs Market by Region: Revenue ($m), 2016
  • Figure 5.2: Global Women's Healthcare Drugs Market by Region: Market Share (%), 2016
  • Figure 5.3: Global Women's Healthcare Drugs Market by Region: AGR 2016-2027 (%)
  • Figure 5.4: Global Women's Healthcare Drugs Market by Region: Market Share Forecast 2017-2027 (%)
  • Figure 5.5: Global Women's Healthcare Drugs Market by Region: Market Share Forecast 2016 (%)
  • Figure 5.6: Global Women's Healthcare Drugs Market by Region: Market Share Forecast 2022 (%)
  • Figure 5.7: Global Women's Healthcare Drugs Market by Region: Market Share Forecast 2027 (%)
  • Figure 5.8: Women's Healthcare
  • Figure 5.9: Women's Healthcare Drugs Market in EU5 by Country: Global Market Share (%), 2016
  • Figure 5.10: Women's Healthcare Drugs Market in EU5 Countries: EU5 Market Share (%), 2016
  • Figure 5.11: Women's Healthcare Drugs Market Forecast in EU5: Revenue ($m), AGR (%),2016-2027
  • Figure 5.12: Women's Healthcare Drugs Market Forecast in the UK: Revenue ($m), AGR (%),2016-2027
  • Figure 5.13: Women's Healthcare Drugs Market Forecast in Germany: Revenue ($m), AGR (%),2016-2027
  • Figure 5.14: Women's Healthcare Drugs Market Forecast in France: Revenue ($m), AGR (%),2016-2027
  • Figure 5.15: Women's Healthcare Drugs Market Forecast in Spain: Revenue ($m), AGR (%),2016-2027
  • Figure 5.16: Women's Healthcare Drugs Market Forecast in Italy: Revenue ($m), AGR (%),2016-2027
  • Figure 5.17: Women's Healthcare Drugs Market Forecast in the RoE: Revenue ($m), AGR (%),2016-2027
  • Figure 5.18: Women's Healthcare Drugs Market Forecast in Japan: Revenue ($m), AGR (%), 2016-2027
  • Figure 5.19: Women's Healthcare Drugs Market Forecast in RoW: Revenue ($m), AGR (%),2016-2027
  • Figure 10.1: Bayer: Sales by Geography (%), 2016
  • Figure 10.2: Bayer: SWOT Analysis
  • Figure 10.3: Eli Lilly: Sales by Geography (%), 2016
  • Figure 10.4: Eli Lilly: SWOT Analysis
  • Figure 10.5: Merck & Co.: Sales by Geography (%), 2016
  • Figure 10.6: Merck & Co.: SWOT Analysis
  • Figure 10.7: Pfizer: Sales by Geography (%), 2016
  • Figure 10.8: Pfizer: SWOT Analysis
  • Figure 10.9: Novartis: SWOT Analysis
  • Figure 10.10: Sanofi: SWOT Analysis
  • Figure 10.11: Sanofi: SWOT Analysis
  • Figure 10.12: Novo Nordisk: Sales by Geography (%), 2016
  • Figure 10.13: AbbVie: SWOT Analysis
  • Figure 10.14: Bristol-Myers Squibb: SWOT Analysis
  • Figure 11.1: Global Women's Healthcare Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)

Companies Listed

  • AbbVie
  • Actavis
  • Adamis Pharmaceuticals
  • Agile Therapeutics
  • Allergan
  • Amgen
  • ANI Pharmaceuticals
  • Apothecus Pharmaceutical
  • AstraZeneca
  • Bayer
  • Bristol-Myers Squibb (BMS)
  • Catalysis
  • Ciba-Geigy
  • Conceptus
  • Crinetics Pharmaceuticals Inc.
  • Dexa Medica Group
  • EffRX
  • Eli Lilly
  • EndoCeutics
  • Ferring International Center
  • Ferring Pharmaceuticals
  • GlaxoSmithKline (GSK)
  • HLL Lifecare
  • Janssen
  • Ligand Pharmaceuticals
  • Lipocine
  • Lupin Pharmaceuticals
  • Mayer Laboratories
  • Medicines 360
  • Merck & Co.
  • Merck KGaA
  • Merus Labs
  • Mylan Laboratories
  • Neurocrine Biosciences
  • Novartis
  • Novo Nordisk
  • OPKO Health
  • Pantarhei Bioscience B.V.
  • Pfizer
  • Radius Health
  • Samsung Bioepsis
  • Sandoz
  • Sanofi
  • Sanofi Pasteur
  • Sanofi Synthelabo
  • Sanofi-Aventis
  • Tarsa Therapeutics
  • Teva Pharmaceuticals
  • Warner Chilcott

List of Organizations Mentioned in the Report

  • American Society for Reproductive Medicine
  • Asia-Pacific Council on Contraception (APCOC)
  • Bill & Melinda Gates Foundation
  • Bristol-Myers Squibb Foundation
  • Catholic medical Mission Board (CMMB)
  • Centers for Disease Control and Prevention (CDC)
  • Department of Health and Human Services (HHS)
  • Deutsche Stiftung Weltbevoelkerung (DSW)
  • European Society of Cardiology (ESC)
  • International Federation of Gynecology and Obstetrics (FIGO)
  • International Federation of Pediatric and Adolescent Gynecology (FIGIJ)
  • International Osteoporosis Foundation (IOF)
  • International Planned Parenthood Federation (IPPF)
  • Pan American Health and Education Foundation (PAHEF)
  • Royal Health Awareness Society
  • Sanofi Espoir Foundation
  • The Heart Truth (US)
  • The National Institute of Health (NIH)
  • The Office of the Surgeon General (US)
  • The Women's Health Initiative (WHI)
  • USAID
  • World Endometriosis Research Foundation
  • World Health Organization (WHO)
Back to Top